First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated malaria
Pyronaridine‐artesunate (PY‐AS) leads to higher first treatment, abnormal ALT increase compared with other antimalarials (high certainty).
1 finding from 1 review
First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated malaria
Pyronaridine‐artesunate (PY‐AS) probably leads to higher first treatment, abnormal AST increase compared with other antimalarials (moderate certainty).
1 finding from 1 review
First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal bilirubin increase compared with other antimalarials (moderate certainty).
1 finding from 1 review
Subsequent treatment(s), abnormal ALT increase · adults and children with uncomplicated malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in subsequent treatment(s), abnormal ALT increase compared with other antimalarials (low certainty).
1 finding from 1 review
Subsequent treatment(s), abnormal AST increase · adults and children with uncomplicated malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in subsequent treatment(s), abnormal AST increase compared with other antimalarials (low certainty).
1 finding from 1 review
Subsequent treatment(s), abnormal bilirubin increase · adults and children with uncomplicated malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in subsequent treatment(s), abnormal bilirubin increase compared with other antimalarials (low certainty).
1 finding from 1 review
First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) may leads to higher first treatment, abnormal ALT increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) may leads to higher first treatment, abnormal AST increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal bilirubin increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
Incidence of coronary artery abnormalities · children diagnosed with Kawasaki disease
Corticosteroids probably leads to lower incidence of coronary artery abnormalities compared with no corticosteroid use (moderate certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol · adults with eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (16 weeks + 4 weeks acute phase) · children and adults with mild to severe eczema
It is very uncertain whether weekend therapy changes systemic adverse events: abnormal cortisol; end of treatment (16… compared with no topical corticosteroid (very low certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema
It is very uncertain whether moderate‐potency changes systemic adverse events: abnormal cortisol; end of treatment (6‐28… compared with mild‐potency topical corticosteroid (very low certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema
1 finding from 1 review
Termination for major abnormality · Fetal ultrasound assessment before 24 weeks' gestation
1 finding from 1 review
Termination of pregnancy for fetal abnormality · Fetal ultrasound assessment before 24 weeks' gestation
Second trimester routine probably leads to higher termination of pregnancy for fetal abnormality compared with selective ultrasound (moderate certainty).
1 finding from 1 review
Adverse effects: abnormal liver function tests · SSNS in children
It is very uncertain whether levamisole changes adverse effects: abnormal liver function tests compared with cyclophosphamide (very low certainty).
1 finding from 1 review
Congenital abnormalities · women with subfertility
1 finding from 1 review